```html

Zollinger‑Ellison Syndrome (ZES) – A Patient‑Focused Medical Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more tumors—called gastrinomas—form in the pancreas or the duodenum (the first part of the small intestine). These tumors secrete excessive amounts of the hormone gastrin, leading to severe, refractory gastric acid hypersecretion. The resulting acid overwhelms the protective mechanisms of the stomach and duodenum, causing painful ulcers, diarrhea, and malabsorption.

Although most cases of ZES occur sporadically, about 20–30 % are associated with a hereditary condition called Multiple Endocrine Neoplasia type 1 (MEN1). (MEN2 is a separate syndrome that includes medullary thyroid carcinoma, pheochromocytoma, and parathyroid tumors; it is **not** linked to ZES.)
ZES can affect anyone, but it is most commonly diagnosed in adults between 30 and 60 years old.

Prevalence: Approximately 1–3 cases per million people worldwide; among patients with MEN1, the prevalence of ZES rises to 20–30 %.<sup>1</sup>

Symptoms

ZES symptoms result from the combination of excess gastric acid and the presence of gastrin‑producing tumors. Not everyone experiences every symptom.

• Recurrent Peptic Ulcers – painful sores in the stomach or duodenum that do not heal with standard therapy.
• Upper Abdominal Pain – burning or gnawing pain that may worsen after meals.
• Diarrhea – watery, often foul‑smelling stools due to rapid gastric emptying and malabsorption.
• Steatorrhea (fatty stools) – caused by fat malabsorption; stools may appear greasy and float.
• Heartburn / Gastro‑esophageal Reflux Disease (GERD) – persistent acid reflux.
• Nausea & Vomiting – especially after large or fatty meals.
• Weight Loss – despite normal or increased appetite, malabsorption leads to unintentional loss.
• Gastrointestinal Bleeding – melena (black, tarry stools) or hematemesis (vomiting blood) from ulcer erosion.
• Abdominal Distention – due to gas and fluid accumulation.
• Fatigue & Anemia – chronic blood loss or malnutrition can cause low hemoglobin.
• Pancreatic or Duodenal Masses – may be palpable or discovered incidentally on imaging.
• Signs of MEN1 (if present) – hyperparathyroidism (kidney stones, bone pain), pituitary tumors (headaches, vision changes), and other endocrine abnormalities.

Causes and Risk Factors

Primary Causes

• Gastrinomas – neuroendocrine tumors arising from enterochromaffin‑like (ECL) cells in the duodenum (≈70 % of cases) or pancreas (≈25 %).
• MEN1 Gene Mutation – autosomal‑dominant inheritance of mutations in the MEN1 tumor suppressor gene on chromosome 11q13. Patients inherit a germline mutation, and a second “hit” leads to tumor formation.

Risk Factors

• Family history of MEN1 or known MEN1 mutation.
• Previous diagnosis of other MEN1‑related tumors (parathyroid, pituitary).
• Age 30‑60 (peak incidence for sporadic ZES).
• Chronic Helicobacter pylori infection does not cause ZES but can exacerbate ulcer symptoms.

Diagnosis

Because ZES presents with ulcer disease that is refractory to conventional therapy, a high index of suspicion is essential.

Step‑by‑step Diagnostic Approach

1. Clinical Evaluation – detailed history of ulcer disease, diarrhea, weight loss, and family history of MEN1.
2. Laboratory Tests
   • Fasting serum gastrin – levels > 1,000 pg/mL (normal < 100) strongly suggest ZES, especially when accompanied by gastric pH < 2.
   • Secretin stimulation test – gastrin rises > 120 pg/mL after IV secretin in ZES (paradoxical response).
   • Basic metabolic panel, CBC, vitamin B12, iron studies to assess for anemia and malnutrition.
3. Imaging for Tumor Localization
   • Endoscopic ultrasound (EUS) – high sensitivity for small pancreatic/duodenal lesions.
   • Contrast‑enhanced CT or MRI – delineates size, vascular involvement, and metastasis.
   • Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT – detects neuroendocrine tumors that express somatostatin receptors.
4. Genetic Testing – recommended for all patients with ZES, especially if < 40 years old or if there is a family history, to identify MEN1 mutations.

Reference: National Institutes of Health (NIH) guidelines for neuroendocrine tumors.<sup>2</sup>

Treatment Options

Therapy targets two main problems: (1) controlling acid hypersecretion, and (2) removing or controlling the gastrinoma.

Acid‑Suppressive Medications

• Proton Pump Inhibitors (PPIs) – high‑dose omeprazole, esomeprazole, or pantoprazole are first‑line; doses often 3‑5 times the standard ulcer dose. PPIs normalize gastric pH, promote ulcer healing, and reduce diarrhea.
• Histamine‑2 Receptor Antagonists (H2 blockers) – less effective than PPIs for ZES; may be added for breakthrough symptoms.

Surgical & Interventional Options

• Curative Resection – when the tumor is localized (most common for duodenal gastrinomas). Options include duodenotomy with excision, pancreaticoduodenectomy (Whipple), or enucleation of small pancreatic lesions.
• Debulking Surgery – for metastatic disease; reduces tumor burden and gastrin production.
• Localized Ablation – radiofrequency ablation or cryo‑ablation for liver metastases.
• Somatostatin Analogue Therapy – octreotide or lanreotide can inhibit gastrin secretion and control tumor growth, especially in unresectable disease.

Systemic Therapies for Advanced Disease

• Targeted agents – everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) are FDA‑approved for progressive pancreatic neuroendocrine tumors.
• Peptide Receptor Radionuclide Therapy (PRRT) – ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive cells; shown to improve progression‑free survival.
• Chemotherapy – rarely needed; regimen depends on differentiation grade.

Lifestyle & Supportive Measures

• Small, frequent meals; low‑fat diet to lessen gastric emptying stimulus.
• Avoid NSAIDs, aspirin, and alcohol, which aggravate ulcer formation.
• Calcium and vitamin D supplementation if PPIs cause malabsorption.
• Regular monitoring of bone density (PPIs & hypergastrinemia can affect bone health).

Living with Zollinger‑Ellison Syndrome (MEN1 Association)

Daily Management Tips

• Adherence to PPIs – never skip a dose; carry a weekly supply when traveling.
• Medication Review – inform every prescriber that you have ZES; many drugs (e.g., clopidogrel) can raise ulcer risk.
• Nutrition – aim for a balanced diet rich in lean protein, complex carbs, and fiber. Use a registered dietitian familiar with malabsorption.
• Hydration – diarrhea can cause electrolyte loss; replace with oral rehydration solutions if needed.
• Routine Follow‑up – at least every 6 months:
  • Serum gastrin level and gastric pH.
  • Imaging (EUS or MRI) to monitor tumor size.
  • Screening for MEN1 complications (parathyroid, pituitary) per endocrinology guidelines.
• Support Networks – connect with patient groups such as the Neuroendocrine Tumor Research Foundation (NETRF) for counseling and updates on clinical trials.
• Vaccinations – keep hepatitis B and pneumococcal vaccines up‑to‑date, especially if you receive systemic therapies that suppress immunity.

Prevention

Because ZES is largely driven by genetic mutations, true primary prevention is limited. However, risk reduction strategies include:

• Genetic Counseling – families with known MEN1 mutations should receive counseling and consider predictive testing for at‑risk relatives.
• Early Surveillance – for mutation carriers, begin annual fasting gastrin measurements and imaging by age 10‑15 (per International MEN1 Consensus). Early detection allows treatment before complications develop.
• Lifestyle Choices – avoiding chronic NSAID use and smoking reduces the additive burden of ulcer disease.

Complications

If untreated or poorly controlled, ZES can lead to serious health problems:

• Perforated Ulcer – a hole in the stomach or duodenal wall leading to peritonitis, a surgical emergency.
• Severe Gastrointestinal Bleeding – may require endoscopic hemostasis or transfusion.
• Intestinal Obstruction – from scarring or tumor growth.
• Malnutrition & Osteoporosis – chronic diarrhea and acid damage impair absorption of iron, calcium, and fat‑soluble vitamins.
• Metastatic Disease – about 25‑35 % of gastrinomas metastasize to the liver or lymph nodes; metastatic disease shortens survival if not managed aggressively.
• MEN1‑Related Complications – hyperparathyroidism (kidney stones, bone disease), pituitary adenomas (vision loss, hormonal imbalance).

When to Seek Emergency Care

References

1. Mayo Clinic. Zollinger‑Ellison Syndrome. https://www.mayoclinic.org/diseases-conditions/zollinger-ellison-syndrome/symptoms-causes/syc-20354069 (accessed June 2026).
2. National Cancer Institute. Pancreatic Neuroendocrine Tumors Treatment (PDQ®). https://www.cancer.gov/types/pancreatic/hp/pancreatic-neuroendocrine-treatment-pdq (accessed June 2026).
3. American Association of Clinical Endocrinology. MEN1 Clinical Practice Guidelines. https://www.aace.com (accessed June 2026).
4. World Health Organization. Classification of Neuroendocrine Tumors. https://www.who.int (accessed June 2026).
5. Center for Disease Control and Prevention. Genetic Testing and Family Health. https://www.cdc.gov (accessed June 2026).
6. Cleveland Clinic. Zollinger‑Ellison Syndrome: Diagnosis & Treatment. https://my.clevelandclinic.org (accessed June 2026).

```